CAMBRIDGE, Mass., Sept. 12 /PRNewswire/ -- Genstruct Inc., a biotechnology company translating the complexity of human biology to develop new successful therapeutics, announced today that its president and CEO, Dr. Keith O. Elliston, has been invited to speak at the Oncology Clinical Trial Summit in Arlington, Va., September 17-18.
Dr. Elliston will participate in a panel discussion focused on "Enhancing Development and Commercial Value Added in Care Delivery and Medicines by Leveraging and Integrating Innovative, Intelligent Technology Platforms." The panel will be moderated by Angeliki Kotsianti, M.D., Ph.D., director, Global Clinical Technology for Pfizer Human Health Technologies and be held on September 17 at 3:30 p.m.
"We understand the challenges of oncology clinical trials and have been focused on developing new approaches with our partnering pharmaceutical companies to deliver actionable hypotheses and mechanistic biomarkers for oncology drug development," said Dr. Keith O. Elliston, president and CEO at Genstruct. "Participating in this panel is a great opportunity to share our causal modeling methodology for translating research results into successful oncology clinical trials and to further improve healthcare delivery to cancer patients."
Dr. Elliston is an invited speaker at many biotechnology and pharmaceutical industry events. He is an experienced entrepreneur and intrapreneur who has dedicated his career to the development of leading-edge technology for drug discovery and drug development. Dr. Elliston spent over 10 years with Merck Research Laboratories, where he served as the Director of Bioinformatics, and the scientific director of the Merck Gene Index project. He then joined Bayer Pharmaceuticals where he founded their global genomics and bioinformatics efforts, and was the section head of Genomics and the worldwide head of Bioinformatics. In 1997 Dr. Elliston joined Gene Logic as Chief Scientific Officer and pioneered the development/application of molecular profiling to drug discovery. He was responsible for the development and management of six pharmaceutical research partnerships representing over $350 million in potential revenues. In 1999, Dr. Elliston founded Viaken Systems, where he was Chairman, President and CEO. He has been an advisor to Oak Investment Partners, Atlas Ventures, and other biotechnology venture capital groups, and has participated in the early stage development of a number of successful biotech companies. Dr. Elliston received an M.S. in genetics from the University of Minnesota, and a Ph.D. in molecular genetics from Rutgers University.
Founded in 2002, Genstruct is a biotechnology company focused on elucidating the complexity of biology for the development of successful therapeutics. By modeling the components within the whole biological system, Genstruct delivers a deep molecular understanding of diseases and drug action, as well as mechanistic biomarkers to accelerate drug discovery and development programs. Genstruct engages in internal discovery and external development partnerships with top tier pharmaceutical companies, which apply systems biology in the areas of oncology, metabolic disorders, cardiovascular diseases and inflammation. The privately held company is based in Cambridge, Mass. For more information, please visit http://www.genstruct.com.
Genstruct and the Genstruct logo are registered trademarks and Molecular Epistemics, Knowledge Assembly, and Epistemics Engine are trademarks of Genstruct, Inc. All other trademarks or registered trademarks are properties of their respective owners.
A & E Communications for Genstruct
|SOURCE Genstruct, Inc.|
Copyright©2007 PR Newswire.
All rights reserved